Literature DB >> 2187814

Calcium is required for binding of Escherichia coli hemolysin (HlyA) to erythrocyte membranes.

D F Boehm1, R A Welch, I S Snyder.   

Abstract

The calcium requirement for hemolytic activity of Escherichia coli hemolysin was investigated by using hemolytic assays and immunoblotting of toxin-treated erythrocytes. The hemolytic activity of cell culture supernatants obtained during growth of E. coli in Luria-Bertani (LB) broth or calcium-free LB broth was calcium dependent. The hemolytic activity of culture supernatants obtained during growth in LB broth supplemented with calcium was calcium independent. Osmotic protection experiments using Dextran 4 to prevent cell lysis indicated that calcium was required for the binding of hemolysin to erythrocytes at both 4 and 37 degrees C. The binding efficiency at 4 degrees C was 50% of that occurring at 37 degrees C. The calcium-dependent binding was confirmed by immunoblotting saline-washed, toxin-treated erythrocytes with a monoclonal antibody after sodium dodecyl sulfate-polyacrylamide gel electrophoresis separation of membrane proteins. Bound hemolysin increased the calcium permeability of the cell membranes as evidenced by calcium-induced membrane protein alterations. The alterations in membrane proteins did not directly cause lysis of the cells. The results were consistent with a mechanism of lysis involving the formation of cation-selective pores in the membranes of target cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187814      PMCID: PMC258749          DOI: 10.1128/iai.58.6.1951-1958.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  Induction of histamine release from rat mast cells and human basophilic granulocytes by clinical Escherichia coli isolates and relation to hemolysin production and adhesin expression.

Authors:  W Gross-Weege; W König; J Scheffer; W Nimmich
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

2.  Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane.

Authors:  G Fairbanks; T L Steck; D F Wallach
Journal:  Biochemistry       Date:  1971-06-22       Impact factor: 3.162

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Membrane damage by pore-forming bacterial cytolysins.

Authors:  S Bhakdi; J Tranum-Jensen
Journal:  Microb Pathog       Date:  1986-02       Impact factor: 3.738

5.  Synthesis and secretion of hemolysin by Escherichia coli.

Authors:  W Springer; W Goebel
Journal:  J Bacteriol       Date:  1980-10       Impact factor: 3.490

6.  Chemical and immunological analysis of the complex structure of Escherichia coli alpha-hemolysin.

Authors:  G A Bohach; I S Snyder
Journal:  J Bacteriol       Date:  1985-12       Impact factor: 3.490

7.  Escherichia coli hemolysin may damage target cell membranes by generating transmembrane pores.

Authors:  S Bhakdi; N Mackman; J M Nicaud; I B Holland
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

8.  Alterations of amino acid repeats in the Escherichia coli hemolysin affect cytolytic activity and secretion.

Authors:  T Felmlee; R A Welch
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Effect of Escherichia coli alpha-hemolysin on human peripheral leukocyte function in vitro.

Authors:  S J Cavalieri; I S Snyder
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

10.  Effect of Escherichia coli hemolysin on permeability of erythrocyte membranes to calcium.

Authors:  S E Jorgensen; P F Mulcahy; C F Louis
Journal:  Toxicon       Date:  1986       Impact factor: 3.033

View more
  28 in total

1.  Secretion of RTX leukotoxin by Actinobacillus actinomycetemcomitans.

Authors:  S C Kachlany; D H Fine; D H Figurski
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

2.  Membrane interaction of Escherichia coli hemolysin: flotation and insertion-dependent labeling by phospholipid vesicles.

Authors:  C Hyland; L Vuillard; C Hughes; V Koronakis
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

3.  The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice.

Authors:  J N Seah; J Frey; J Kwang
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

Review 4.  Host-pathogen interactions in urinary tract infection.

Authors:  Greta R Nielubowicz; Harry L T Mobley
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

5.  Hemolytic activity in the periodontopathogen Porphyromonas gingivalis: kinetics of enzyme release and localization.

Authors:  L Chu; T E Bramanti; J L Ebersole; S C Holt
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

6.  Purification and characterization of a hemolysin-like protein, Sll1951, a nontoxic member of the RTX protein family from the Cyanobacterium Synechocystis sp. strain PCC 6803.

Authors:  Tetsushi Sakiyama; Hironori Ueno; Hideya Homma; Osamu Numata; Tomohiko Kuwabara
Journal:  J Bacteriol       Date:  2006-05       Impact factor: 3.490

7.  Separable domains define target cell specificities of an RTX hemolysin from Actinobacillus pleuropneumoniae.

Authors:  D R McWhinney; Y F Chang; R Young; D K Struck
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

Review 8.  The different hemolysins of Escherichia coli.

Authors:  L Beutin
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

9.  Characterization of binding of adenylate cyclase toxin to target cells by flow cytometry.

Authors:  M C Gray; W Ross; K Kim; E L Hewlett
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

10.  The C-terminal domain is essential for protective activity of the Bordetella pertussis adenylate cyclase-hemolysin.

Authors:  F Betsou; P Sebo; N Guiso
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.